Literature DB >> 10690794

Pneumococcal vaccine in the elderly: the Norwegian experience.

I S Aaberge1.   

Abstract

Pneumococcal infections have increased during the last 10 to 15 years in Norway. Their incidence is now about 20 per 100,000 population for all age groups, but is 2 to 3 times higher among the elderly. In 1996, the Advisory Board of Infectious Disease Control, National Institute of Public Health, Norway, recommended that pneumococcal polysaccharide vaccine should be administered to all individuals aged > or = 65 years. This recommendation has led to an increased use of pneumococcal vaccine, with a marked peak during the influenza vaccination season.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10690794     DOI: 10.2165/00002512-199915001-00005

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  17 in total

1.  Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people.

Authors:  J E Sisk; A J Moskowitz; W Whang; J D Lin; D S Fedson; A M McBean; J F Plouffe; M S Cetron; J C Butler
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

2.  Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group.

Authors:  A Ortqvist; J Hedlund; L A Burman; E Elbel; M Höfer; M Leinonen; I Lindblad; B Sundelöf; M Kalin
Journal:  Lancet       Date:  1998-02-07       Impact factor: 79.321

3.  Increase in bacteraemic pneumococcal infections in children.

Authors:  M Baer; R Vuento; T Vesikari
Journal:  Lancet       Date:  1995-03-11       Impact factor: 79.321

4.  Risk of pneumococcal disease in individuals without a spleen.

Authors:  P Aavitsland; L O Frøholm; E A Høiby; A Lystad
Journal:  Lancet       Date:  1994-11-26       Impact factor: 79.321

5.  Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial.

Authors:  I Koivula; M Stén; M Leinonen; P H Mäkelä
Journal:  Am J Med       Date:  1997-10       Impact factor: 4.965

6.  Pneumococcal bacteraemia during a recent decade.

Authors:  A Kuikka; J Syrjänen; O V Renkonen; V V Valtonen
Journal:  J Infect       Date:  1992-03       Impact factor: 6.072

7.  Incidence of invasive pneumococcal disease and distribution of capsular types of pneumococci in Denmark, 1989-94.

Authors:  S V Nielsen; J Henrichsen
Journal:  Epidemiol Infect       Date:  1996-12       Impact factor: 2.451

8.  Systemic pneumococcal disease after staging splenectomy for Hodgkin's disease 1969-1980 without pneumococcal vaccine protection: a follow-up study 1994.

Authors:  A Foss Abrahamsen; E A Høiby; E Hannisdal; O G Jørgensen; H Holte; V Hasseltvedt; H Høst
Journal:  Eur J Haematol       Date:  1997-02       Impact factor: 2.997

Review 9.  Invasive pneumococcal infections: incidence, predisposing factors, and prognosis.

Authors:  L A Burman; R Norrby; B Trollfors
Journal:  Rev Infect Dis       Date:  1985 Mar-Apr

10.  The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

Authors:  E D Shapiro; A T Berg; R Austrian; D Schroeder; V Parcells; A Margolis; R K Adair; J D Clemens
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.